CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 01, 2017	Jul. 02, 2016
Cash Flows from Operating Activities:
Net income (loss)	$ 20,137	$ (10,346)
Non-cash items:
Depreciation and amortization	21,789	22,544
Gain on divestiture	(8,000)	0
Provision for losses on accounts receivable and inventory	928	2,571
Stock-based compensation expense	1,343	1,840
Impairment of assets	0	1,766
Other non-cash operating activities	658	(650)
Change in operating assets and liabilities:
Change in accounts receivable	2,203	8,239
Change in inventories	1,417	(3,721)
Change in prepaid income taxes	817	(932)
Change in other assets and other liabilities	8,998	1,126
Change in accounts payable and accrued expenses	(11,865)	8,258
Net cash provided by operating activities	38,425	30,695
Cash Flows from Investing Activities:
Capital expenditures	(13,721)	(22,479)
Proceeds from divestiture	9,000	0
Proceeds from sale of property, plant and equipment	981	87
Net cash used in investing activities	(3,740)	(22,392)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(11,856)	(7,114)
Proceeds from employee stock purchase plan	1,622	1,980
Proceeds from exercise of stock options	6,430	1,409
Net increase (decrease) in short-term loans	255	(1,261)
Net cash used in financing activities	(3,549)	(4,986)
Effect of exchange rates on cash and cash equivalents	1,039	(192)
Net Change in Cash and Cash Equivalents	32,175	3,125
Cash and Cash Equivalents at Beginning of Period	139,564	115,123
Cash and Cash Equivalents at End of Period	171,739	118,248
Supplemental Disclosures of Cash Flow Information:
Interest paid	1,825	2,072
Income taxes paid	2,151	1,541
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 1,338	$ 1,764